Full Press Release Details
SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION
We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016. We believe the presentation of our historical segment financial information by new reportable segment provides useful supplemental information to investors to better understand the impact of segment changes.
Exhibit I: provides a reconciliation of the Company s previously reported GAAP segment financial results to Adjusted Earnings (Non-GAAP) supplemental to our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company s financial results as determined by generally accepted accounting principles ( GAAP ), McKesson Corporation (the Company or we ) also presents the following Non-GAAP measures in this press release. The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors ability to compare its financial results to those of other companies in the same industry. However, the Company s Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
Amortization of acquisition-related intangibles - Amortization expenses of intangible assets directly related to business combinations and/or the formation of joint ventures and equity method investments.
Acquisition-related expenses and adjustments - Transaction, integration and other expenses that are directly related to business combinations, the formation of joint ventures and the Healthcare Technology Net Asset Exchange. Examples include transaction closing costs, professional service fees, legal fees, restructuring or severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees, gains or losses related to foreign currency contracts entered into directly due to acquisitions, gains or losses on business combinations, and gain on the Healthcare Technology Net Asset Exchange.
LIFO inventory-related adjustments - LIFO inventory-related non-cash expense or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company s share of antitrust lawsuit settlements.
Restructuring charges - Non-acquisition related restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, and/or Company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which includes normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded. These restructuring charges are reflected under various captions within our operating expenses.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our Adjusted Earnings from time to time. While not all-inclusive, other adjustments may include: gains or losses from divestitures of businesses that do not qualify as discontinued operations and from dispositions of assets; asset impairments; adjustments to claim and litigation reserves for estimated probable losses; certain discrete benefits related to the December 2017 enactment of the 2017 Tax Cuts and Jobs Act; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification ( ASC ) 740, Income Taxes, which is the same accounting principle used by the Company when presenting its GAAP financial results.
Additionally, our equity method investments financial results are adjusted for the above noted items.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company internally uses Non-GAAP financial measures in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. The Company conducts its business internationally in local currencies, including Euro, British pound sterling and Canadian dollars. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present constant currency information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations. Nonetheless, Non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL YEAR AND FISCAL QUARTERS OF 2018
| Quarter Ended June 30, 2017 | Quarter Ended September 30, 2017 | Quarter Ended December 31, 2017 | Quarter Ended March 31, 2018 | Year Ended March 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | ||||||||||||||||||||||||||||||||||||||||||||||
| REVENUES | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | $ | 40,282 | $ | $ | 40,282 | $ | 40,603 | $ | $ | 40,603 | $ | 41,969 | $ | $ | 41,969 | $ | 39,733 | $ | $ | 39,733 | $ | 162,587 | $ | $ | 162,587 | |||||||||||||||||||||||||||||||||||
| European Pharmaceutical Solutions | 6,382 | 6,382 | 6,773 | 6,773 | 6,989 | 6,989 | 7,176 | 7,176 | 27,320 | 27,320 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 1,533 | 1,533 | 1,660 | 1,660 | 1,693 | 1,693 | 1,725 | 1,725 | 6,611 | 6,611 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other (1) | 2,854 | 2,854 | 3,025 | 3,025 | 2,966 | 2,966 | 2,994 | 2,994 | 11,839 | 11,839 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues | $ | 51,051 | $ | $ | 51,051 | $ | 52,061 | $ | $ | 52,061 | $ | 53,617 | $ | $ | 53,617 | $ | 51,628 | $ | $ | 51,628 | $ | 208,357 | $ | $ | 208,357 | |||||||||||||||||||||||||||||||||||
| OPERATING PROFIT | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | $ | 475 | $ | 54 | $ | 529 | $ | 710 | $ | (40 | ) | $ | 670 | $ | 565 | $ | 40 | $ | 605 | $ | 785 | $ | (23 | ) | $ | 762 | $ | 2,535 | $ | 31 | $ | 2,566 | ||||||||||||||||||||||||||||
| European Pharmaceutical Solutions | 35 | 49 | 84 | (547 | ) | 636 | 89 | 16 | 69 | 85 | (1,185 | ) | 1,267 | 82 | (1,681 | ) | 2,021 | 340 | ||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 108 | 17 | 125 | 118 | 18 | 136 | 123 | 18 | 141 | 112 | 30 | 142 | 461 | 83 | 544 | |||||||||||||||||||||||||||||||||||||||||||||
| Other (1) (2) | 17 | 214 | 231 | 74 | 167 | 241 | 180 | 33 | 213 | (378 | ) | 621 | 243 | (107 | ) | 1,035 | 928 | |||||||||||||||||||||||||||||||||||||||||||
| Operating profit | 635 | 334 | 969 | 355 | 781 | 1,136 | 884 | 160 | 1,044 | (666 | ) | 1,895 | 1,229 | 1,208 | 3,170 | 4,378 | ||||||||||||||||||||||||||||||||||||||||||||
| Corporate | (109 | ) | (3 | ) | (112 | ) | (108 | ) | 15 | (93 | ) | (120 | ) | 13 | (107 | ) | (227 | ) | 21 | (206 | ) | (564 | ) | 46 | (518 | ) | ||||||||||||||||||||||||||||||||||
| Income from continuing operations before interest expense and income taxes | $ | 526 | $ | 331 | $ | 857 | $ | 247 | $ | 796 | $ | 1,043 | $ | 764 | $ | 173 | $ | 937 | $ | (893 | ) | $ | 1,916 | $ | 1,023 | $ | 644 | $ | 3,216 | $ | 3,860 | |||||||||||||||||||||||||||||
| OPERATING PROFIT AS A % OF REVENUES | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | 1.18 | % | 1.31 | % | 1.75 | % | 1.65 | % | 1.35 | % | 1.44 | % | 1.98 | % | 1.92 | % | 1.56 | % | 1.58 | % | ||||||||||||||||||||||||||||||||||||||||
| European Pharmaceutical Solutions | 0.55 | 1.32 | (8.08 | ) | 1.31 | 0.23 | 1.22 | (16.51 | ) | 1.14 | (6.15 | ) | 1.24 | |||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 7.05 | 8.15 | 7.11 | 8.19 | 7.27 | 8.33 | 6.49 | 8.23 | 6.97 | 8.23 |
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL 2016 - 2017
| Year Ended March 31, 2017 | Year Ended March 31, 2016 | |||||||||||||||||||||||
| As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | As Reported (GAAP) | Adjustments | Adjusted Earnings (Non-GAAP) | |||||||||||||||||||
| REVENUES | ||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | $ | 155,236 | $ | $ | 155,236 | $ | 149,222 | $ | $ | 149,222 | ||||||||||||||
| European Pharmaceutical Solutions | 24,847 | 24,847 | 23,497 | 23,497 | ||||||||||||||||||||
| Medical-Surgical Solutions | 6,244 | 6,244 | 6,033 | 6,033 | ||||||||||||||||||||
| Other (1) | 12,206 | 12,206 | 12,132 | 12,132 | ||||||||||||||||||||
| Revenues | $ | 198,533 | $ | $ | 198,533 | $ | 190,884 | $ | $ | 190,884 | ||||||||||||||
| OPERATING PROFIT | ||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | $ | 2,488 | $ | (2 | ) | $ | 2,486 | $ | 2,879 | $ | 296 | $ | 3,175 | |||||||||||
| European Pharmaceutical Solutions | 173 | 262 | 435 | 149 | 310 | 459 | ||||||||||||||||||
| Medical-Surgical Solutions | 401 | 86 | 487 | 280 | 123 | 403 | ||||||||||||||||||
| Other (1) (2) | 4,514 | (3,542 | ) | 972 | 764 | 119 | 883 | |||||||||||||||||
| Operating profit | 7,576 | (3,196 | ) | 4,380 | 4,072 | 848 | 4,920 | |||||||||||||||||
| Corporate | (377 | ) | (4 | ) | (381 | ) | (469 | ) | 19 | (450 | ) | |||||||||||||
| Income from continuing operations before interest expense and income taxes | $ | 7,199 | $ | (3,200 | ) | $ | 3,999 | $ | 3,603 | $ | 867 | $ | 4,470 | |||||||||||
| OPERATING PROFIT AS A % OF REVENUES | ||||||||||||||||||||||||
| U.S. Pharmaceutical and Specialty Solutions | 1.60 | % | 1.60 | % | 1.93 | % | 2.13 | % | ||||||||||||||||
| European Pharmaceutical Solutions | 0.70 | 1.75 | 0.63 | 1.95 | ||||||||||||||||||||
| Medical-Surgical Solutions | 6.42 | 7.80 | 4.64 | 6.68 |